CClinicalTrials.gg
Not yet recruitingNCT07714083Updated Sep 30, 2026

Cognitive Processing Therapy for Posttraumatic Stress Disorder and Co-occurring Lived Experience Stress

An interventional study of Standard CPT and CPT-LEAP in Post Traumatic Stress Disorder, sponsored by Boston University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Boston University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Populations facing health disparities include groups with significantly higher rates of posttraumatic stress disorder than the general population who frequently experience lived experience stress, which may complicate posttraumatic stress disorder symptom presentations. However, there are currently no posttraumatic stress disorder treatments designed to meet the unique needs of these individuals.

The proposed study will pilot an adaptation of Cognitive Processing Therapy (a gold-standard treatment for posttraumatic stress disorder) that has been modified to incorporate the impact of lived experience stress as an additional treatment target. This project has the potential to advance our understanding of how to enhance Cognitive Processing Therapy in order to optimize posttraumatic stress disorder treatment response and mitigate health disparities.

Read the detailed description

This study will occur in two phases.

Phase 1 will involve refining Cognitive Processing Therapy Lived Experience Adapted Protocol (CPT-LEAP) and includes beta testing of CPT-LEAP (n=6).

Phase 2 will involve a pilot RCT in which participants (n=52) will be randomized (1:1) to standard CPT or CPT-LEAP. The investigators anticipate 26 participants will be enrolled in each treatment arm.

02

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • Cognitive Processing Therapy (CPT)
  • Lived experience stress
  • Lived Experience Adapted Protocol (LEAP)
  • Veterans
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current diagnosis of PTSD
  • Self-identification as a sexual or gender minority (SGM) individual
  • Endorsement of SGM stress experiences with moderate distress
  • For patients who take psychiatric medication, stable dose one month prior to enrollment
  • Reside in Massachusetts.

Exclusion criteria

Exclusion Criteria:

  • Current active suicidal or homicidal ideation with intent or plan
  • Unstable bipolar disorder/current mania
  • Unstable psychotic disorder/current psychosis
  • Current severe substance use that warrants immediate medical attention
  • Cognitive impairment or organic disorder (e.g., advanced dementia, severe traumatic brain injury) that impairs ability to complete CPT procedures
  • Past completion of CPT or current trauma-focused treatment
  • Unwillingness to consent to audio or video recording of assessment and treatment sessions
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Cognitive Therapy Processing Therapy - Lived Experience Adapted Protocol (CPT--LEAP)

    Participants randomized to this arm will receive the adapted CPT-LEAP treatment delivered in weekly one-hour sessions, using the CPT variable length format in line with standard VA practice (9-15 sessions).

    Behavioral: CPT-LEAP

  • Active comparator
    Standard Cognitive Therapy Processing (CPT)

    Participants randomized to this arm will receive standard CPT treatment delivered in weekly one-hour sessions, using the CPT variable length format in line with standard VA practice (9-15 sessions).

    Behavioral: Standard CPT

Interventions

  • BehavioralStandard CPT

    CPT focuses on teaching skills to identify and challenge PTSD-maintaining maladaptive beliefs related to the trauma itself, the world, and oneself. Worksheets and assignments are given between each session.

  • BehavioralCPT-LEAP

    CPT-LEAP frames each session in relation to beliefs about both traumatic and lived experience stressors and their interactions and impacts, including not only beliefs about oneself, others, and the world, but also one's identity, and use of relevant examples throughout the protocol.

05

What researchers measure

Primary outcomes

  1. Post traumatic stress disorder symptoms (PTSD)

    Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 (CAPS-5). The CAPS-5 includes 20 items assessing PTSD symptom severity. Total scores range from 0-80 with higher scores indicating more severe PTSD symptoms.

    Time frame: immediately after treatment, 3 months

06

Study locations

1 site
  • VA Boston Healthcare System
    Jamaica Plain, Massachusetts 02130, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07714083
Lead sponsor
Boston University
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Mar 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Cara Herbitter, PhD, MPH
Contact
Cara.Herbitter@va.gov
857-364-6528
Cara Herbitter, PhD, MPH
principal investigator · Psychiatry CABUSM and National Center for PTSD, VA Boston Healthcare System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion